<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="228177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111085</url>
  </required_header>
  <id_info>
    <org_study_id>AC-054-201</org_study_id>
    <nct_id>NCT00111085</nct_id>
  </id_info>
  <brief_title>Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)</brief_title>
  <acronym>CONSCIOUS-1</acronym>
  <official_title>A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After aSAH by Intravenous Administration of Clazosentan, a Selective ETA Receptor Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure how effective and safe three different doses of the
      drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of 3 dose levels (1 mg/h, 5 mg/h and 15 mg/h) of clazosentan in preventing the occurrence of cerebral vasospasm following aSAH.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the ability of clazosentan to reduce the occurrence of early morbidity/mortality.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of clazosentan on clinical outcome.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of three dose levels of clazosentan.</measure>
  </secondary_outcome>
  <enrollment type="Actual">413</enrollment>
  <condition>Vasospasm Following Subarachnoid Hemorrhage</condition>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <condition>Intracranial Vasospasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clazosentan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged 18 to 70 years (inclusive) or male patients aged 45 to 70
             (inclusive) or males aged 18 to 44 (inclusive) who are surgically or naturally
             sterile or can personally sign the core Informed Consent

          -  Patients with a ruptured saccular aneurysm that has been confirmed by digital
             subtraction angiography (DSA) and for which clipping or coiling (endovascular
             obliteration) is possible.

          -  Patients with a diffuse or localized thick subarachnoid clot on baseline CT scan.

          -  Start of screening within 48 hours post onset of aSAH clinical symptoms.

          -  WFNS Grades I-IV, and those Grade V patients who improve to Grade IV or less after
             ventriculostomy.

        Exclusion Criteria:

          -  Patients with SAH due to other causes (e.g., trauma or rupture of fusiform or mycotic
             aneurysms)

          -  Patients with intraventricular or intracerebral blood, in the absence of subarachnoid
             blood.

          -  No visualized clot or presence of only localized thin clot on CT

          -  Presence of any degree of cerebral vasospasm on screening angiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Giuseppe Lanzino</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horner</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Aldrich</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ogilvy</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Zuccarello</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Woo</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rosenwasser</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Zager</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. George A. Lopez</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bullock</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wong</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Findlay</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Redekop</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ferguson</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bojanowski</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Fleetwood</name>
      <address>
        <city>Halifax, Nova Scotia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 11, 2010</lastchanged_date>
  <firstreceived_date>May 17, 2005</firstreceived_date>
  <firstreceived_results_disposition_date>February 11, 2010</firstreceived_results_disposition_date>
  <keyword>aneurysmal subarachnoid hemorrhage (aSAH)</keyword>
  <keyword>vasospasm</keyword>
  <keyword>delayed ischemic neurological deficits (DIND)</keyword>
  <keyword>computer tomography scan (CT scan)</keyword>
  <keyword>digital subtraction angiography (DSA)</keyword>
  <keyword>endothelin A receptor</keyword>
  <keyword>clazosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
